Assessing the prospect of donepezil in improving cognitive impairment in patients with schizophrenia

Expert Opinion on Investigational Drugs

Volumn 22, Issue 2, 2013, Pages 259-265

  Thakurathi, Neelam ^a   Vincenzi, Brenda ^a   Henderson, David C ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Acetylcholinesterase inhibitor; Atypical antipsychotics; Cognitive impairments; Donepezil; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; DONEPEZIL; FLUPHENAZINE; OLANZAPINE; PIMOZIDE; PLACEBO; QUETIAPINE; RISPERIDONE; TACRINE; ZIPRASIDONE;

ALZHEIMER DISEASE; ARTICLE; ATTENTION; CLINICAL ASSESSMENT; COGNITIVE DEFECT; CRYSTAL STRUCTURE; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG MEGADOSE; EXECUTIVE FUNCTION; FOOD AND DRUG ADMINISTRATION; HUMAN; IC 50; LEARNING; LIVER TOXICITY; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SHORT TERM MEMORY; TREATMENT DURATION; VERBAL MEMORY; VISUAL MEMORY; WORKING MEMORY;

BINDING SITES; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; HUMANS; INDANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PIPERIDINES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 84872182044     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.750650     Document Type: Article

References (47)

1. Jablensky A, Sartorius N, Ernberg G, et al. Schizophrenia: Manifestations, incidence and course in different cultures: A World Health Organization ten-country study. Psychol Med Monogr SUPPL1992;20:1-97
2. Mueser KT, McGurk SR. Schizophrenia. Lancet 2004;363(9426):2063-72 (Pubitemid 38781110)
3. Sharma T, Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr Clin North Am 2003;26(1):25-40 (Pubitemid 36384346)
4. Keefe RS, Silva SG, Perkins DO, et al. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-Analysis. Schizophr Bull 1999;25(2):201-22 (Pubitemid 29272501)
5. Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001;158(2):176-84 (Pubitemid 32116511)
6. Manschreck TC, Boshes RA. The CATIE schizophrenia trial: Results, impact, controversy. Harv Rev Psychiatry 2007;15(5):245-58 (Pubitemid 47557208)
7. Keefe RS, Bilder RM, Harvey PD, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 2006;31(9):2033-46
8. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007;64(6):633-47 (Pubitemid 46878665)
9. Keefe RS, Mohs RC, Bilder RM, et al. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: Development, methodology, and rationale. Schizophr Bull 2003;29(1):45-55 (Pubitemid 36871056)
10. Davis KL, Kahn RS, Ko G, et al. Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry 1991;148(11):1474-86
11. Gelenberg AJ, et al. Maintaining metabolic and cardiovascular health in patients with schizophrenia: Perspectives in long-Term care. Monograph, University of Florida. Medscape CME 2004
12. El-Mallakh RS, Kirch DG, Shelton R, et al. The nucleus basalis of meynert, senile plaques, and intellectual impairment in schizophrenia. J Neuropsychiatry Clin Neurosci 1991;3(4):383-6
13. Karson CN, Mrak RE, Husain MM, et al. Decreased mesopontine choline acetyltransferase levels in schizophrenia. Mol Chem Neuropathol 1996;29(2):181-91
14. Green MF. What are the functional consequences of neurocognitive deficits in schizophreniä Am J Psychiatry 1996;153(3):321-30 (Pubitemid 26074706)
15. Friedman JI. Cholinergic targets for cognitive enhancement in schizophrenia: Focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology (Berl) 2004;174(1):45-53 (Pubitemid 38925090)
16. Furey ML, Pietrini P, Haxby JV. Cholinergic enhancement and increased selectivity of perceptual processing during working memory. Science 2000;290(5500):2315-19 (Pubitemid 32041576)
17. Hasselmo ME, Bower JM. Acetylcholine and memory. Trends Neurosci 1993;16(6):218-22 (Pubitemid 23139185)
18. Dean B, McLeod M, Keriakous D, et al. Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Molecular Psychiatry 2002;7(10):1083-91 (Pubitemid 36044267)
19. Raedler TJ, Knable MB, Jones DW, et al. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry 2003;160(1):118-27 (Pubitemid 36042435)
20. Freedman R, Hall M, Adler LE, et al. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 1995;38(1):22-33
21. Goff DC, Henderson DC, Amico E. Cigarette smoking in schizophrenia: Relationship to psychopathology and medication side effects. Am J Psychiatry 1992;149(9):1189-94
22. McEvoy JP, Allen TB. Substance abuse (including nicotine) in schizophrenic patients. Curr Opin Psychiatry 2003;16(2):199
23. Levin ED, Wilson W, Rose JE, McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 1996;15(5):429-436 (Pubitemid 26389866)
24. Dalack GW, Healy DJ, Meador-Woodruff JH. Nicotine dependence in schizophrenia: Clinical phenomena and laboratory findings. Am J Psychiatry 1998;155(11):1490-501 (Pubitemid 28512015)
25. Winkler J, Thal LJ, Gage FH, et al. Cholinergic strategies for Alzheimer's disease. J Mol Med 1998;76(8):555-67 (Pubitemid 28332724)
26. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006(1):CD005593
27. Kryger G, Silman I, Sussman JL. Structure of acetylcholinesterase complexed with E2020 (Aricept-): Implications for the design of new anti-Alzheimer drugs. Structure 1999;7(3):297-307 (Pubitemid 29159689)
28. Cheng DH, Ren H, Tang XC. Huperzine A, a novel promising acetylcholinesterase inhibitor. Neuroreport 1996;8(1):97
29. Sugimoto H, Iimura Y, Yamanishi Y, et al. Synthesis and structure-Activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5, 6-Dimethoxy-1-oxoindan-2-yl) methyl] piperidine hydrochloride and related compounds. J Med Chem 1995;38(24):4821-9
30. Rogers S, Friedhoff L. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br J Clin Pharmacol 1998;46(S1):1
31. Akhondzadeh S, Gerami M, Noroozian M, et al. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(8):1810-15
32. Fagerlund B, Søholm B, Fink-Jensen A, et al. Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: A double-blind, placebo-controlled study. Clin Neuropharmacol 2007;30(1):3
33. Freudenreich O, Herz L, Deckersbach T, et al. Added donepezil for stable schizophrenia: A double-blind, placebo-controlled trial. Psychopharmacology (Berl) 2005;181(2):358-63 (Pubitemid 41492206)
34. Friedman JI, Adler DN, Howanitz E, et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry 2002;51(5):349-57 (Pubitemid 34251171)
35. Keefe RSE, Malhotra AK, Meltzer HY, et al. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: Significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 2007;33(6):1217-28
36. Kohler CG, Martin EA, Kujawski E, et al. No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia. Cogn Neuropsychiatry 2007;12(5):412-21 (Pubitemid 47254593)
37. Nahas Z, George MS, Horner MD, et al. Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: A pilot double-blind placebo controlled BOLD fMRI study. Neurocase 2003;9(3):274-82 (Pubitemid 36949473)
38. Tugal O, Yazici KM, Anil Yaǧcioǧlu AE, et al. A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int J Neuropsychopharmacol 2004;7(2):117-23 (Pubitemid 38823278)
39. Tuma M, Lenderova Z, Zemanova M, et al. P. 2.158 Donepezil as an adjunctive treatment of cognitive dysfunction in schizophrenia. Eur Neuropsychopharmacol 2003;13:S348-9
40. Bora E, Veznedaroglu B, Kayahan B. The effect of galantamine added to clozapine on cognition of five patients with schizophrenia. Clin Neuropharmacol 2005;28(3):139-41 (Pubitemid 40923414)
41. Schubert MH, Young KA, Hicks PB. Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol Psychiatry 2006;60(6):530-3 (Pubitemid 44402376)
42. Dyer MA, Freudenreich O, Culhane MA, et al. High-Dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophr Res 2008;102(1):88-95
43. Buchanan R, Conley RR, Dickinson D, et al. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 2008;165(1):82-9 (Pubitemid 351704556)
44. Lee SW, Lee JG, Lee BJ, et al. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Int Clin Psychopharmacol 2007;22(2):63-8
45. Singh J, Kour K, Jayaram MB. Acetylcholinesterase inhibitors for schizophrenia. The Cochrane Library. Cochrane Database Syst Rev 2012; 1:CD007967
46. Mitchell JE, Dahlgren A. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986;143(8):993-7 (Pubitemid 16073948)
47. Kelly C, McCreadiev RG. Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. Am J Psychiatry 1999;156(11):1751-7 (Pubitemid 29517568)